Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma
NCT ID: NCT03763370
Last Updated: 2024-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
NCT05208307
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
NCT07285239
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04126200
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
NCT03828292
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd)
Drug: Belantamab mafodotin
•Belantamab mafodotin 2.5 milligram per kilogram (mg/kg) intravenous (IV) will be administered at every cycle, once every 3 Weeks, on Day 1 of every cycle, until completion of treatment.
Drug: Bortezomib •Bortezomib will be administered based on the full prescribing information, for the first 8 Cycles
Drug: Dexamethasone
•Dexamethasone will be administered based on the full prescribing information, for the first 8 Cycles
Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)
Drug: Belantamab mafodotin:
* Cycle 1: Belantamab mafodotin 2.5 mg/kg IV administered once
* Cycle 2 onward: Belantamab mafodotin 1.9 mg/kg IV administered once every 4 weeks until completion of treatment
Drug: Pomalidomide •Pomalidomide will be administered at every cycle, based on the full prescribing information
Drug: Dexamethasone
•Dexamethasone will be administered at every cycle, based on the full prescribing information
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of multiple myeloma and/or plasma cell dyscrasias and either:
1. For combination with bortezomib/dexamethasone; previously treated with at least 1 prior line of MM therapy and must have documented disease progression during or after their most recent therapy OR
2. For combination with pomalidomide/dexamethasone; have been previously treated with at least 1 prior line of MM therapy including a lenalidomide-containing regimen (lenalidomide must have been administered for at least 2 consecutive cycles) and must have documented disease progression during or after their most recent therapy.
3. Able to obtain ophthalmic examinations at baseline, before the next 3 subsequent treatment cycles and as clinically indicated on treatment
4. Contraception requirements
A. Female Participants: A female patient is eligible to participate if one of the following conditions applies:
I. The patient Is not a woman of childbearing potential (WOCBP) OR II. The patient Is a WOCBP and using an effective contraceptive method during treatment with belantamab mafodotin and for 4 months after the last dose. The patient must also have a negative highly sensitive serum pregnancy test within 72 hours of dosing on Cycle 1 Day 1. Please discuss with GSK physician if the patient is pregnant, breast-feeding or planning to have a baby.
B. Male participants with female partners of child-bearing potential are eligible to participate if they agree to use effective contraception during treatment with belantamab mafodotin until 6 months after the last dose
Exclusion Criteria
2. Alanine transaminase (ALT) \>2.5x upper limit of normal (ULN).
3. Total bilirubin \>1.5xULN; patients with Gilbert's syndrome can be included with total bilirubin \>1.5xULN as long as direct bilirubin is ≤1.5xULN.
4. Cirrhosis or current unstable liver or biliary disease per physician assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices, persistent jaundice.
5. Patients with Hepatitis B will be excluded unless:
1. HbcAb positive, HBsAg negative: HBV deoxyribonucleic acid (DNA) undetectable and Antiviral treatment instituted if HBV DNA becomes detectable
2. HBsAg positive at screen or within 3 months prior to first dose: HBV DNA undetectable and Antiviral treatment maintained throughout program treatment
6. Patients with positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of program treatment unless:
1. RNA test negative
2. Successful anti-viral treatment followed by a negative HCV RNA test after a washout period of at least 4 weeks
7. Evidence of Active Bleeding requiring intervention
8. Currently Active Graft-versus-host disease (GvHD)
9. Known Hypersensitivity to the active substance or to any of the excipients
10. Previous progression on belantamab mafodotin
11. Active infection requiring treatment
12. Previous participation in DREAMM-7 or DREAMM-8 clinical trials
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
If you are a Healthcare Professional who would like to request compassionate use of a GSK investigational medicine for a patient, please use the GSK Compassionate Use Request Portal.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
209233
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.